Search - tctmd.com

Displaying 1 - 20 of 57

Sort: Relevancy | Date

News Conference News TCT 2025

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

L.A. McKeown

October 27, 2025

News Conference News TCT 2021

Good Long-term Results With FANTOM BVS, but More Data Needed

Michael O'Riordan

October 21, 2021

News Conference News TCT 2020

OPTIMIZE: Svelte Direct Stenting Device Fails to Match DES

L.A. McKeown

October 17, 2020

News Conference News TCT 2020

Prophylactic PCI of Vulnerable Plaques? PROSPECT II/ABSORB

Michael O'Riordan

October 14, 2020

News Conference News TCT 2019

Ultrathin-Strut Orsiro Stent as Good as BioMatrix: BIODEGRADE

Michael O'Riordan

September 30, 2019

Even With PSP, Bioresorbable Scaffold Falls Short in ABSORB-COMPARE and ABSORB IV Trials

News Conference News TCT 2018

Even With PSP, Bioresorbable Scaffold Falls Short in COMPARE-ABSORB and ABSORB IV Trials

Michael O'Riordan

September 25, 2018

News Opinion Editor's Corner TCT 2018

TCT 2018, Day Four: Bioresorbable Scaffolds, Renal Denervation, Head-to-Head TAVR, INOCA, and . . . That’s a Wrap!

Shelley Wood

September 25, 2018

News Conference News TCT 2017

Long-term Absorb BVS Data Continue to Disappoint

Michael O'Riordan

October 31, 2017

News Conference News TCT 2016

RIBS VI: El SVB Absorb es Seguro en el Manejo de la Reestenosis Intra-stent pero No Supera al Stent Metálico Xience

Michael O'Riordan

November 08, 2016

News Conference News TCT 2016

RIBS VI: Absorb BVS Safe in In-Stent Restenosis but Fails to Best Xience Metallic Stent

Michael O'Riordan

November 08, 2016

News Conference News TCT 2016

RIBS VI：Absorb BVS 支架内再狭窄方面安全，但没有好过 Xience 金属支架

Michael O'Riordan

November 08, 2016

News Conference News TCT 2016

New BRS Studies Show Promise for Second-Generation Devices With Thinner Struts

Yael L. Maxwell

October 31, 2016

News Conference News TCT 2016

‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent

Michael O'Riordan

October 30, 2016

Presentation TCT 2016

ABSORB II: Three-Year Clinical Outcomes From a Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Vascular Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Presenter: David W.M. Muller, Jonathan M. Hill, Patrick W. Serruys

October 30, 2016

Presentation TCT 2016

ABSORB China: Two-Year Clinical Outcomes From a Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Vascular Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Presenter: David W.M. Muller, Jonathan M. Hill, Runlin Gao

October 30, 2016

News Conference News TCT 2015

PANDA III: BuMA SES Noninferior to Excel SES for TLF at 1 Year

October 14, 2015

News Conference News TCT 2015

ABSORB III: Novel Bioresorbable Scaffold as Good as Standard-of-Care DES

Yael L. Maxwell

October 12, 2015

News Conference News TCT 2015

ABSORB II: Absorb BVS, Xience Yield Similar Outcomes at 2 Years

October 12, 2015

News Conference News TCT 2015

Absorb BVS Matches Xience V in Chinese Patients

Todd Neale

October 12, 2015

News Conference News TCT 2015

BIOSOLVE-II: Novel Absorbable Scaffold Safe, Effective

October 12, 2015

Advertisement

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

Good Long-term Results With FANTOM BVS, but More Data Needed

OPTIMIZE: Svelte Direct Stenting Device Fails to Match DES

Prophylactic PCI of Vulnerable Plaques? PROSPECT II/ABSORB

Ultrathin-Strut Orsiro Stent as Good as BioMatrix: BIODEGRADE

Even With PSP, Bioresorbable Scaffold Falls Short in COMPARE-ABSORB and ABSORB IV Trials

TCT 2018, Day Four: Bioresorbable Scaffolds, Renal Denervation, Head-to-Head TAVR, INOCA, and . . . That’s a Wrap!

Long-term Absorb BVS Data Continue to Disappoint

RIBS VI: El SVB Absorb es Seguro en el Manejo de la Reestenosis Intra-stent pero No Supera al Stent Metálico Xience

RIBS VI: Absorb BVS Safe in In-Stent Restenosis but Fails to Best Xience Metallic Stent

RIBS VI：Absorb BVS 支架内再狭窄方面安全，但没有好过 Xience 金属支架

New BRS Studies Show Promise for Second-Generation Devices With Thinner Struts

‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent

ABSORB II: Three-Year Clinical Outcomes From a Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Vascular Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

ABSORB China: Two-Year Clinical Outcomes From a Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Vascular Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

PANDA III: BuMA SES Noninferior to Excel SES for TLF at 1 Year

ABSORB III: Novel Bioresorbable Scaffold as Good as Standard-of-Care DES

ABSORB II: Absorb BVS, Xience Yield Similar Outcomes at 2 Years

Absorb BVS Matches Xience V in Chinese Patients

BIOSOLVE-II: Novel Absorbable Scaffold Safe, Effective

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content